119 related articles for article (PubMed ID: 12705166)
1. [Disease-modifying treatment of MS--progress with complications].
Fagius J
Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
[No Abstract] [Full Text] [Related]
2. Time is money for nurse with MS. Interview by Esther Leach.
Beeley D
Nurs Times; 1999 Jul 7-13; 95(27):16-7. PubMed ID: 10524119
[No Abstract] [Full Text] [Related]
3. [Interferon-beta in multiple sclerosis--who is going to be treated?].
Aarli JA
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
[No Abstract] [Full Text] [Related]
4. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
5. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
[No Abstract] [Full Text] [Related]
6. Combination therapy for treatment of multiple sclerosis.
Lublin FD; Reingold SC
Ann Neurol; 1998 Jul; 44(1):7-9. PubMed ID: 9667587
[No Abstract] [Full Text] [Related]
7. [Nursing service for MS patients].
Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16518890
[No Abstract] [Full Text] [Related]
8. [Interferon beta treatment of disseminated sclerosis in Denmark--current status].
Sørensen PS
Ugeskr Laeger; 2000 Nov; 162(45):6091-3. PubMed ID: 11107953
[No Abstract] [Full Text] [Related]
9. [High doses of interferon in the treatment of multiple sclerosis].
Muñoz D
Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
[No Abstract] [Full Text] [Related]
10. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
Bryant J; Clegg A; Milne R
BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
[No Abstract] [Full Text] [Related]
11. [Treatment of multiple sclerosis].
Midgard R
Tidsskr Nor Laegeforen; 2001 Aug; 121(19):2254. PubMed ID: 11571873
[No Abstract] [Full Text] [Related]
12. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
Freedman MS; Forrestal FG
Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta1b in multiple sclerosis.
Buttmann M; Rieckmann P
Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
[TBL] [Abstract][Full Text] [Related]
14. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
15. [Place of residence determines access to interferon-beta therapy in MS. Less than 15 per cent of patients are treated--big differences between the counties].
Andersson A; Persson PM; Fredrikson S
Lakartidningen; 1999 Dec; 96(49):5492-5. PubMed ID: 10643243
[TBL] [Abstract][Full Text] [Related]
16. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
McNaughton H; Kayes N; McPherson K
N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
19. Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?
Chaudhuri A; Behan PO
BMJ; 2003 May; 326(7400):1213. PubMed ID: 12775634
[No Abstract] [Full Text] [Related]
20. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
